RAS, wanted dead or alive: Advances in targeting RAS mutant cancers.

Abstract excerpt

Oncogenic RAS proteins, which are mutated in approximately 24% of all human cancers, have earned a well-deserved reputation as being "undruggable." However, several studies have challenged that reputation. With the first small molecules that directly target one oncogenic RAS mutant (G12C) undergoing clinical evaluation, there have been substantial advances in finding anti-RAS therapeutic strategies. Furthermore,...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to ras Proteins
• Share to Mutation
• Share to Neoplasm Proteins